Inhibits reuptake of serotonin and norepinephrine in CNS
The bioavailability of tramadol hydrochloride after intramuscular injection or intravenous administration is the same; the mean peak serum concentration is achieved after 45 minutes. Tramadol hydrochloride is primarily metabolised in the liver (90%) with one of its metabolites, mono-O-desmethyltramadol (M1), being 2 to 4 times as potent as the parent compound. Tramadol hydrochloride has a linear pharmacokinetic profile within the therapeutic dosage range.
Tramadol hydrochloride and its metabolites are excreted mainly in the urine. The elimination half-life is 5 to 7 hours, but is prolonged in impaired hepatic and renal function.
Tramadol hydrochloride crosses the blood-brain and placental barrier. Small amounts are excreted in breast milk unchanged or as the metabolite M1.
Moderate to moderately severe pain
• Hypersensitivity to drug, its components, or opioids
• Acute intoxication with alcohol, sedative-hypnotics, centrally acting analgesics, opioid analgesics, or psychotropic agents
• Physical opioid dependence
Use cautiously in:
• seizure disorder or risk factors for seizures, renal or hepatic impairment, increased intracranial pressure, head trauma, acute abdomen
• history of opioid dependence or recent use of large opioid doses
• elderly patients
• pregnant or breastfeeding patients
• children younger than age 16 (safety not established)
Anesthetics, antihistamines, CNS depressants, other opioids, psychotropic agents, sedative-hypnotics: increased risk of CNS depression
Carbamazepine: increased tramadol metabolism and decreased efficacy
MAO inhibitors: increased risk of serotonin syndrome and seizures
CNS: dizziness, vertigo, headache, drowsiness, anxiety, stimulation, confusion, incoordination, euphoria, nervousness, sleep disorder, asthenia, hypertonia, seizures
CV: vasodilation
EENT: visual disturbances
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, flatulence, dry mouth, anorexia
GU: urinary retention and frequency, proteinuria, menopausal symptoms
Respiratory: respiratory depression (with large doses, concomitant anesthetic use, or alcohol ingestion)
Skin: pruritus, sweating
Other: physical or psychological drug dependence, drug tolerance
• Storage: Store below 30 C°
• Protect from light and freezing
Tramadol Injection 50mg / 1ml : 5 ampoules/box
Tramadic®
Injection50mg/1ml
Opioid agonist
Analgesic
category C
Inhibits reuptake of serotonin and norepinephrine in CNS
The bioavailability of tramadol hydrochloride after intramuscular injection or intravenous administration is the same; the mean peak serum concentration is achieved after 45 minutes. Tramadol hydrochloride is primarily metabolised in the liver (90%) with one of its metabolites, mono-O-desmethyltramadol (M1), being 2 to 4 times as potent as the parent compound. Tramadol hydrochloride has a linear pharmacokinetic profile within the therapeutic dosage range.
Tramadol hydrochloride and its metabolites are excreted mainly in the urine. The elimination half-life is 5 to 7 hours, but is prolonged in impaired hepatic and renal function.
Tramadol hydrochloride crosses the blood-brain and placental barrier. Small amounts are excreted in breast milk unchanged or as the metabolite M1.
Moderate to moderately severe pain
• Hypersensitivity to drug, its components, or opioids
• Acute intoxication with alcohol, sedative-hypnotics, centrally acting analgesics, opioid analgesics, or psychotropic agents
• Physical opioid dependence
Use cautiously in:
• seizure disorder or risk factors for seizures, renal or hepatic impairment, increased intracranial pressure, head trauma, acute abdomen
• history of opioid dependence or recent use of large opioid doses
• elderly patients
• pregnant or breastfeeding patients
• children younger than age 16 (safety not established)
Anesthetics, antihistamines, CNS depressants, other opioids, psychotropic agents, sedative-hypnotics: increased risk of CNS depression
Carbamazepine: increased tramadol metabolism and decreased efficacy
MAO inhibitors: increased risk of serotonin syndrome and seizures
CNS: dizziness, vertigo, headache, drowsiness, anxiety, stimulation, confusion, incoordination, euphoria, nervousness, sleep disorder, asthenia, hypertonia, seizures
CV: vasodilation
EENT: visual disturbances
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, flatulence, dry mouth, anorexia
GU: urinary retention and frequency, proteinuria, menopausal symptoms
Respiratory: respiratory depression (with large doses, concomitant anesthetic use, or alcohol ingestion)
Skin: pruritus, sweating
Other: physical or psychological drug dependence, drug tolerance
• Storage: Store below 30 C°
• Protect from light and freezing
Tramadol Injection 50mg / 1ml : 5 ampoules/box
Tramadic®
[view] =>Tramadic®
) ) [field_contraindications] => Array ( [0] => Array ( [value] => • Hypersensitivity to drug, its components, or opioids • Acute intoxication with alcohol, sedative-hypnotics, centrally acting analgesics, opioid analgesics, or psychotropic agents • Physical opioid dependence [format] => 1 [safe] =>• Hypersensitivity to drug, its components, or opioids
• Acute intoxication with alcohol, sedative-hypnotics, centrally acting analgesics, opioid analgesics, or psychotropic agents
• Physical opioid dependence
• Hypersensitivity to drug, its components, or opioids
• Acute intoxication with alcohol, sedative-hypnotics, centrally acting analgesics, opioid analgesics, or psychotropic agents
• Physical opioid dependence
Injection50mg/1ml
[view] =>Injection50mg/1ml
) ) [field_drug_interactions] => Array ( [0] => Array ( [value] => Anesthetics, antihistamines, CNS depressants, other opioids, psychotropic agents, sedative-hypnotics: increased risk of CNS depression Carbamazepine: increased tramadol metabolism and decreased efficacy MAO inhibitors: increased risk of serotonin syndrome and seizures [format] => 1 [safe] =>Anesthetics, antihistamines, CNS depressants, other opioids, psychotropic agents, sedative-hypnotics: increased risk of CNS depression
Carbamazepine: increased tramadol metabolism and decreased efficacy
MAO inhibitors: increased risk of serotonin syndrome and seizures
Anesthetics, antihistamines, CNS depressants, other opioids, psychotropic agents, sedative-hypnotics: increased risk of CNS depression
Carbamazepine: increased tramadol metabolism and decreased efficacy
MAO inhibitors: increased risk of serotonin syndrome and seizures
Moderate to moderately severe pain
[view] =>Moderate to moderately severe pain
) ) [field_packing] => Array ( [0] => Array ( [value] => Tramadol Injection 50mg / 1ml : 5 ampoules/box [format] => 1 [safe] =>Tramadol Injection 50mg / 1ml : 5 ampoules/box
[view] =>Tramadol Injection 50mg / 1ml : 5 ampoules/box
) ) [field_pdf] => Array ( [0] => Array ( [fid] => 156 [uid] => 1 [filename] => 8-tramadic.pdf [filepath] => sites/default/files/pdf/8-tramadic.pdf [filemime] => application/pdf [filesize] => 130173 [status] => 1 [timestamp] => 1329482979 [list] => 1 [data] => [i18nsync] => 1 [nid] => 210 [view] => ) ) [field_pharmacokinetics] => Array ( [0] => Array ( [value] => The bioavailability of tramadol hydrochloride after intramuscular injection or intravenous administration is the same; the mean peak serum concentration is achieved after 45 minutes. Tramadol hydrochloride is primarily metabolised in the liver (90%) with one of its metabolites, mono-O-desmethyltramadol (M1), being 2 to 4 times as potent as the parent compound. Tramadol hydrochloride has a linear pharmacokinetic profile within the therapeutic dosage range. Tramadol hydrochloride and its metabolites are excreted mainly in the urine. The elimination half-life is 5 to 7 hours, but is prolonged in impaired hepatic and renal function. Tramadol hydrochloride crosses the blood-brain and placental barrier. Small amounts are excreted in breast milk unchanged or as the metabolite M1. [format] => 1 [safe] =>The bioavailability of tramadol hydrochloride after intramuscular injection or intravenous administration is the same; the mean peak serum concentration is achieved after 45 minutes. Tramadol hydrochloride is primarily metabolised in the liver (90%) with one of its metabolites, mono-O-desmethyltramadol (M1), being 2 to 4 times as potent as the parent compound. Tramadol hydrochloride has a linear pharmacokinetic profile within the therapeutic dosage range.
Tramadol hydrochloride and its metabolites are excreted mainly in the urine. The elimination half-life is 5 to 7 hours, but is prolonged in impaired hepatic and renal function.
Tramadol hydrochloride crosses the blood-brain and placental barrier. Small amounts are excreted in breast milk unchanged or as the metabolite M1.
The bioavailability of tramadol hydrochloride after intramuscular injection or intravenous administration is the same; the mean peak serum concentration is achieved after 45 minutes. Tramadol hydrochloride is primarily metabolised in the liver (90%) with one of its metabolites, mono-O-desmethyltramadol (M1), being 2 to 4 times as potent as the parent compound. Tramadol hydrochloride has a linear pharmacokinetic profile within the therapeutic dosage range.
Tramadol hydrochloride and its metabolites are excreted mainly in the urine. The elimination half-life is 5 to 7 hours, but is prolonged in impaired hepatic and renal function.
Tramadol hydrochloride crosses the blood-brain and placental barrier. Small amounts are excreted in breast milk unchanged or as the metabolite M1.
Opioid agonist
[view] =>Opioid agonist
) ) [field_precautions] => Array ( [0] => Array ( [value] => Use cautiously in: • seizure disorder or risk factors for seizures, renal or hepatic impairment, increased intracranial pressure, head trauma, acute abdomen • history of opioid dependence or recent use of large opioid doses • elderly patients • pregnant or breastfeeding patients • children younger than age 16 (safety not established) [format] => 1 [safe] =>Use cautiously in:
• seizure disorder or risk factors for seizures, renal or hepatic impairment, increased intracranial pressure, head trauma, acute abdomen
• history of opioid dependence or recent use of large opioid doses
• elderly patients
• pregnant or breastfeeding patients
• children younger than age 16 (safety not established)
Use cautiously in:
• seizure disorder or risk factors for seizures, renal or hepatic impairment, increased intracranial pressure, head trauma, acute abdomen
• history of opioid dependence or recent use of large opioid doses
• elderly patients
• pregnant or breastfeeding patients
• children younger than age 16 (safety not established)
category C
[view] =>category C
) ) [field_references] => Array ( [0] => Array ( [value] => [format] => [safe] => [view] => ) ) [field_side_effects] => Array ( [0] => Array ( [value] => CNS: dizziness, vertigo, headache, drowsiness, anxiety, stimulation, confusion, incoordination, euphoria, nervousness, sleep disorder, asthenia, hypertonia, seizures CV: vasodilation EENT: visual disturbances GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, flatulence, dry mouth, anorexia GU: urinary retention and frequency, proteinuria, menopausal symptoms Respiratory: respiratory depression (with large doses, concomitant anesthetic use, or alcohol ingestion) Skin: pruritus, sweating Other: physical or psychological drug dependence, drug tolerance [format] => 1 [safe] =>CNS: dizziness, vertigo, headache, drowsiness, anxiety, stimulation, confusion, incoordination, euphoria, nervousness, sleep disorder, asthenia, hypertonia, seizures
CV: vasodilation
EENT: visual disturbances
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, flatulence, dry mouth, anorexia
GU: urinary retention and frequency, proteinuria, menopausal symptoms
Respiratory: respiratory depression (with large doses, concomitant anesthetic use, or alcohol ingestion)
Skin: pruritus, sweating
Other: physical or psychological drug dependence, drug tolerance
CNS: dizziness, vertigo, headache, drowsiness, anxiety, stimulation, confusion, incoordination, euphoria, nervousness, sleep disorder, asthenia, hypertonia, seizures
CV: vasodilation
EENT: visual disturbances
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, flatulence, dry mouth, anorexia
GU: urinary retention and frequency, proteinuria, menopausal symptoms
Respiratory: respiratory depression (with large doses, concomitant anesthetic use, or alcohol ingestion)
Skin: pruritus, sweating
Other: physical or psychological drug dependence, drug tolerance
• Storage: Store below 30 C°
• Protect from light and freezing
• Storage: Store below 30 C°
• Protect from light and freezing
Analgesic
[view] =>Analgesic
) ) [field_related_products] => Array ( [0] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [view] => ) [1] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [view] => ) [2] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [view] => ) ) [taxonomy] => Array ( [2] => stdClass Object ( [tid] => 2 [vid] => 1 [name] => Anlagesics, Anti-inflammatory Drugs [description] => [weight] => 0 [language] => [trid] => 0 [v_weight_unused] => 0 ) ) [build_mode] => 0 [readmore] => [content] => Array ( [field_one_image] => Array ( [#type_name] => product [#context] => full [#field_name] => field_one_image [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => -3 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => image_plain [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_one_image [#weight] => 0 [#theme] => imagefield_formatter_image_plain [#item] => Array ( [fid] => 157 [uid] => 1 [filename] => 8-tramadic_s.jpg [filepath] => sites/default/files/images/8-tramadic_s_0.jpg [filemime] => image/jpeg [filesize] => 55878 [status] => 1 [timestamp] => 1329483042 [list] => 1 [data] => Array ( [alt] => [title] => ) [i18nsync] => 1 [nid] => 210 [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] => ) [#title] => [#description] => [#children] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_one_image [#title] => Image [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] => [#printed] => 1 ) [#title] => [#description] => [#children] =>Tramadic®
[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>Tramadic®
) [#title] => [#description] => [#children] =>Tramadic®
[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_brand_name [#title] => Brand Name [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>Tramadic®
[#printed] => 1 ) [#title] => [#description] => [#children] =>Tramadic®
Injection50mg/1ml
[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>Injection50mg/1ml
) [#title] => [#description] => [#children] =>Injection50mg/1ml
[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_dosage_form [#title] => Dosage Form [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>Injection50mg/1ml
[#printed] => 1 ) [#title] => [#description] => [#children] =>Injection50mg/1ml
Opioid agonist
[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>Opioid agonist
) [#title] => [#description] => [#children] =>Opioid agonist
[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_pharmacological_category [#title] => Pharmacological Category [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>Opioid agonist
[#printed] => 1 ) [#title] => [#description] => [#children] =>Opioid agonist
Analgesic
[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>Analgesic
) [#title] => [#description] => [#children] =>Analgesic
[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_therapeutic_category [#title] => Therapeutic Category [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>Analgesic
[#printed] => 1 ) [#title] => [#description] => [#children] =>Analgesic
category C
[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>category C
) [#title] => [#description] => [#children] =>category C
[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_pregnancy_category [#title] => Pregnancy Category [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>category C
[#printed] => 1 ) [#title] => [#description] => [#children] =>category C
Inhibits reuptake of serotonin and norepinephrine in CNS
[#title] => [#description] => [#printed] => 1 ) [field_pharmacokinetics] => Array ( [#type_name] => product [#context] => full [#field_name] => field_pharmacokinetics [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 4 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_pharmacokinetics [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => The bioavailability of tramadol hydrochloride after intramuscular injection or intravenous administration is the same; the mean peak serum concentration is achieved after 45 minutes. Tramadol hydrochloride is primarily metabolised in the liver (90%) with one of its metabolites, mono-O-desmethyltramadol (M1), being 2 to 4 times as potent as the parent compound. Tramadol hydrochloride has a linear pharmacokinetic profile within the therapeutic dosage range. Tramadol hydrochloride and its metabolites are excreted mainly in the urine. The elimination half-life is 5 to 7 hours, but is prolonged in impaired hepatic and renal function. Tramadol hydrochloride crosses the blood-brain and placental barrier. Small amounts are excreted in breast milk unchanged or as the metabolite M1. [format] => 1 [safe] =>The bioavailability of tramadol hydrochloride after intramuscular injection or intravenous administration is the same; the mean peak serum concentration is achieved after 45 minutes. Tramadol hydrochloride is primarily metabolised in the liver (90%) with one of its metabolites, mono-O-desmethyltramadol (M1), being 2 to 4 times as potent as the parent compound. Tramadol hydrochloride has a linear pharmacokinetic profile within the therapeutic dosage range.
Tramadol hydrochloride and its metabolites are excreted mainly in the urine. The elimination half-life is 5 to 7 hours, but is prolonged in impaired hepatic and renal function.
Tramadol hydrochloride crosses the blood-brain and placental barrier. Small amounts are excreted in breast milk unchanged or as the metabolite M1.
The bioavailability of tramadol hydrochloride after intramuscular injection or intravenous administration is the same; the mean peak serum concentration is achieved after 45 minutes. Tramadol hydrochloride is primarily metabolised in the liver (90%) with one of its metabolites, mono-O-desmethyltramadol (M1), being 2 to 4 times as potent as the parent compound. Tramadol hydrochloride has a linear pharmacokinetic profile within the therapeutic dosage range.
Tramadol hydrochloride and its metabolites are excreted mainly in the urine. The elimination half-life is 5 to 7 hours, but is prolonged in impaired hepatic and renal function.
Tramadol hydrochloride crosses the blood-brain and placental barrier. Small amounts are excreted in breast milk unchanged or as the metabolite M1.
The bioavailability of tramadol hydrochloride after intramuscular injection or intravenous administration is the same; the mean peak serum concentration is achieved after 45 minutes. Tramadol hydrochloride is primarily metabolised in the liver (90%) with one of its metabolites, mono-O-desmethyltramadol (M1), being 2 to 4 times as potent as the parent compound. Tramadol hydrochloride has a linear pharmacokinetic profile within the therapeutic dosage range.
Tramadol hydrochloride and its metabolites are excreted mainly in the urine. The elimination half-life is 5 to 7 hours, but is prolonged in impaired hepatic and renal function.
Tramadol hydrochloride crosses the blood-brain and placental barrier. Small amounts are excreted in breast milk unchanged or as the metabolite M1.
The bioavailability of tramadol hydrochloride after intramuscular injection or intravenous administration is the same; the mean peak serum concentration is achieved after 45 minutes. Tramadol hydrochloride is primarily metabolised in the liver (90%) with one of its metabolites, mono-O-desmethyltramadol (M1), being 2 to 4 times as potent as the parent compound. Tramadol hydrochloride has a linear pharmacokinetic profile within the therapeutic dosage range.
Tramadol hydrochloride and its metabolites are excreted mainly in the urine. The elimination half-life is 5 to 7 hours, but is prolonged in impaired hepatic and renal function.
Tramadol hydrochloride crosses the blood-brain and placental barrier. Small amounts are excreted in breast milk unchanged or as the metabolite M1.
The bioavailability of tramadol hydrochloride after intramuscular injection or intravenous administration is the same; the mean peak serum concentration is achieved after 45 minutes. Tramadol hydrochloride is primarily metabolised in the liver (90%) with one of its metabolites, mono-O-desmethyltramadol (M1), being 2 to 4 times as potent as the parent compound. Tramadol hydrochloride has a linear pharmacokinetic profile within the therapeutic dosage range.
Tramadol hydrochloride and its metabolites are excreted mainly in the urine. The elimination half-life is 5 to 7 hours, but is prolonged in impaired hepatic and renal function.
Tramadol hydrochloride crosses the blood-brain and placental barrier. Small amounts are excreted in breast milk unchanged or as the metabolite M1.
Moderate to moderately severe pain
[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>Moderate to moderately severe pain
) [#title] => [#description] => [#children] =>Moderate to moderately severe pain
[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_indications [#title] => Indications [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>Moderate to moderately severe pain
[#printed] => 1 ) [#title] => [#description] => [#children] =>Moderate to moderately severe pain
• Hypersensitivity to drug, its components, or opioids
• Acute intoxication with alcohol, sedative-hypnotics, centrally acting analgesics, opioid analgesics, or psychotropic agents
• Physical opioid dependence
• Hypersensitivity to drug, its components, or opioids
• Acute intoxication with alcohol, sedative-hypnotics, centrally acting analgesics, opioid analgesics, or psychotropic agents
• Physical opioid dependence
• Hypersensitivity to drug, its components, or opioids
• Acute intoxication with alcohol, sedative-hypnotics, centrally acting analgesics, opioid analgesics, or psychotropic agents
• Physical opioid dependence
• Hypersensitivity to drug, its components, or opioids
• Acute intoxication with alcohol, sedative-hypnotics, centrally acting analgesics, opioid analgesics, or psychotropic agents
• Physical opioid dependence
• Hypersensitivity to drug, its components, or opioids
• Acute intoxication with alcohol, sedative-hypnotics, centrally acting analgesics, opioid analgesics, or psychotropic agents
• Physical opioid dependence
Use cautiously in:
• seizure disorder or risk factors for seizures, renal or hepatic impairment, increased intracranial pressure, head trauma, acute abdomen
• history of opioid dependence or recent use of large opioid doses
• elderly patients
• pregnant or breastfeeding patients
• children younger than age 16 (safety not established)
Use cautiously in:
• seizure disorder or risk factors for seizures, renal or hepatic impairment, increased intracranial pressure, head trauma, acute abdomen
• history of opioid dependence or recent use of large opioid doses
• elderly patients
• pregnant or breastfeeding patients
• children younger than age 16 (safety not established)
Use cautiously in:
• seizure disorder or risk factors for seizures, renal or hepatic impairment, increased intracranial pressure, head trauma, acute abdomen
• history of opioid dependence or recent use of large opioid doses
• elderly patients
• pregnant or breastfeeding patients
• children younger than age 16 (safety not established)
Use cautiously in:
• seizure disorder or risk factors for seizures, renal or hepatic impairment, increased intracranial pressure, head trauma, acute abdomen
• history of opioid dependence or recent use of large opioid doses
• elderly patients
• pregnant or breastfeeding patients
• children younger than age 16 (safety not established)
Use cautiously in:
• seizure disorder or risk factors for seizures, renal or hepatic impairment, increased intracranial pressure, head trauma, acute abdomen
• history of opioid dependence or recent use of large opioid doses
• elderly patients
• pregnant or breastfeeding patients
• children younger than age 16 (safety not established)
Anesthetics, antihistamines, CNS depressants, other opioids, psychotropic agents, sedative-hypnotics: increased risk of CNS depression
Carbamazepine: increased tramadol metabolism and decreased efficacy
MAO inhibitors: increased risk of serotonin syndrome and seizures
Anesthetics, antihistamines, CNS depressants, other opioids, psychotropic agents, sedative-hypnotics: increased risk of CNS depression
Carbamazepine: increased tramadol metabolism and decreased efficacy
MAO inhibitors: increased risk of serotonin syndrome and seizures
Anesthetics, antihistamines, CNS depressants, other opioids, psychotropic agents, sedative-hypnotics: increased risk of CNS depression
Carbamazepine: increased tramadol metabolism and decreased efficacy
MAO inhibitors: increased risk of serotonin syndrome and seizures
Anesthetics, antihistamines, CNS depressants, other opioids, psychotropic agents, sedative-hypnotics: increased risk of CNS depression
Carbamazepine: increased tramadol metabolism and decreased efficacy
MAO inhibitors: increased risk of serotonin syndrome and seizures
Anesthetics, antihistamines, CNS depressants, other opioids, psychotropic agents, sedative-hypnotics: increased risk of CNS depression
Carbamazepine: increased tramadol metabolism and decreased efficacy
MAO inhibitors: increased risk of serotonin syndrome and seizures
CNS: dizziness, vertigo, headache, drowsiness, anxiety, stimulation, confusion, incoordination, euphoria, nervousness, sleep disorder, asthenia, hypertonia, seizures
CV: vasodilation
EENT: visual disturbances
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, flatulence, dry mouth, anorexia
GU: urinary retention and frequency, proteinuria, menopausal symptoms
Respiratory: respiratory depression (with large doses, concomitant anesthetic use, or alcohol ingestion)
Skin: pruritus, sweating
Other: physical or psychological drug dependence, drug tolerance
CNS: dizziness, vertigo, headache, drowsiness, anxiety, stimulation, confusion, incoordination, euphoria, nervousness, sleep disorder, asthenia, hypertonia, seizures
CV: vasodilation
EENT: visual disturbances
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, flatulence, dry mouth, anorexia
GU: urinary retention and frequency, proteinuria, menopausal symptoms
Respiratory: respiratory depression (with large doses, concomitant anesthetic use, or alcohol ingestion)
Skin: pruritus, sweating
Other: physical or psychological drug dependence, drug tolerance
CNS: dizziness, vertigo, headache, drowsiness, anxiety, stimulation, confusion, incoordination, euphoria, nervousness, sleep disorder, asthenia, hypertonia, seizures
CV: vasodilation
EENT: visual disturbances
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, flatulence, dry mouth, anorexia
GU: urinary retention and frequency, proteinuria, menopausal symptoms
Respiratory: respiratory depression (with large doses, concomitant anesthetic use, or alcohol ingestion)
Skin: pruritus, sweating
Other: physical or psychological drug dependence, drug tolerance
CNS: dizziness, vertigo, headache, drowsiness, anxiety, stimulation, confusion, incoordination, euphoria, nervousness, sleep disorder, asthenia, hypertonia, seizures
CV: vasodilation
EENT: visual disturbances
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, flatulence, dry mouth, anorexia
GU: urinary retention and frequency, proteinuria, menopausal symptoms
Respiratory: respiratory depression (with large doses, concomitant anesthetic use, or alcohol ingestion)
Skin: pruritus, sweating
Other: physical or psychological drug dependence, drug tolerance
CNS: dizziness, vertigo, headache, drowsiness, anxiety, stimulation, confusion, incoordination, euphoria, nervousness, sleep disorder, asthenia, hypertonia, seizures
CV: vasodilation
EENT: visual disturbances
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, flatulence, dry mouth, anorexia
GU: urinary retention and frequency, proteinuria, menopausal symptoms
Respiratory: respiratory depression (with large doses, concomitant anesthetic use, or alcohol ingestion)
Skin: pruritus, sweating
Other: physical or psychological drug dependence, drug tolerance
• Storage: Store below 30 C°
• Protect from light and freezing
• Storage: Store below 30 C°
• Protect from light and freezing
• Storage: Store below 30 C°
• Protect from light and freezing
• Storage: Store below 30 C°
• Protect from light and freezing
• Storage: Store below 30 C°
• Protect from light and freezing
Tramadol Injection 50mg / 1ml : 5 ampoules/box
[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>Tramadol Injection 50mg / 1ml : 5 ampoules/box
) [#title] => [#description] => [#children] =>Tramadol Injection 50mg / 1ml : 5 ampoules/box
[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_packing [#title] => Packing [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>Tramadol Injection 50mg / 1ml : 5 ampoules/box
[#printed] => 1 ) [#title] => [#description] => [#children] =>Tramadol Injection 50mg / 1ml : 5 ampoules/box
Tramadic®
Injection50mg/1ml
Opioid agonist
Analgesic
category C
Inhibits reuptake of serotonin and norepinephrine in CNS
The bioavailability of tramadol hydrochloride after intramuscular injection or intravenous administration is the same; the mean peak serum concentration is achieved after 45 minutes. Tramadol hydrochloride is primarily metabolised in the liver (90%) with one of its metabolites, mono-O-desmethyltramadol (M1), being 2 to 4 times as potent as the parent compound. Tramadol hydrochloride has a linear pharmacokinetic profile within the therapeutic dosage range.
Tramadol hydrochloride and its metabolites are excreted mainly in the urine. The elimination half-life is 5 to 7 hours, but is prolonged in impaired hepatic and renal function.
Tramadol hydrochloride crosses the blood-brain and placental barrier. Small amounts are excreted in breast milk unchanged or as the metabolite M1.
Moderate to moderately severe pain
• Hypersensitivity to drug, its components, or opioids
• Acute intoxication with alcohol, sedative-hypnotics, centrally acting analgesics, opioid analgesics, or psychotropic agents
• Physical opioid dependence
Use cautiously in:
• seizure disorder or risk factors for seizures, renal or hepatic impairment, increased intracranial pressure, head trauma, acute abdomen
• history of opioid dependence or recent use of large opioid doses
• elderly patients
• pregnant or breastfeeding patients
• children younger than age 16 (safety not established)
Anesthetics, antihistamines, CNS depressants, other opioids, psychotropic agents, sedative-hypnotics: increased risk of CNS depression
Carbamazepine: increased tramadol metabolism and decreased efficacy
MAO inhibitors: increased risk of serotonin syndrome and seizures
CNS: dizziness, vertigo, headache, drowsiness, anxiety, stimulation, confusion, incoordination, euphoria, nervousness, sleep disorder, asthenia, hypertonia, seizures
CV: vasodilation
EENT: visual disturbances
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, flatulence, dry mouth, anorexia
GU: urinary retention and frequency, proteinuria, menopausal symptoms
Respiratory: respiratory depression (with large doses, concomitant anesthetic use, or alcohol ingestion)
Skin: pruritus, sweating
Other: physical or psychological drug dependence, drug tolerance
• Storage: Store below 30 C°
• Protect from light and freezing
Tramadol Injection 50mg / 1ml : 5 ampoules/box
(C) Copyright Caspian Tamin Pharmaceutical Co.
All Rights Reserved.